ArticleCell2020
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19.
Article in Cell, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 1,256 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
School Studies Within the EuCARE Horizon Europe Research Project (EUCARE-SCHOOLS Study)
An Experimental Medicine Decipher of a Minimum Correlate of Cellular Immunity
Who cites it
1,256 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- CKD-related impairment in humoral and cellular immune response and potential correlation with long COVID-19: a systematic review.Frontiers in immunology · 2025Pooled it
- Immunogenicity and safety of the booster COVID-19 vaccine among people with HIV: a systematic review and meta-analysis.Frontiers in immunology · 2025Pooled it
- Cell-Mediated Immunity of mRNA-1283 Vaccine Encoding SARS-CoV-2 Spike Receptor-Binding and N-Terminal Domains in Preclinical and Clinical Studies.The Journal of infectious diseases · 2026Trial
- Evaluation of Cellular Immune Responses After mRNA-1273 Vaccination in Children 6 Months to 11 Years of Age.The Journal of infectious diseases · 2025Trial
- An open-label study on the safety and immunogenicity of a PD-1-enhanced DNA vaccine used as a T cell booster for COVID-19.EBioMedicine · 2025Trial
- SARS-CoV-2-induced IgG repertoires shape T cell responses, microRNA regulation, and autoreactivity according to disease severity.Journal of translational autoimmunity · 2026Article
- Signs of Cross-Reactivity Between SARS-CoV-2 and Other Coronaviruses in a Pre-Vaccine Swedish School Setting.Acta paediatrica (Oslo, Norway : 1992) · 2026Article
- Integrated Assessment of Humoral and Cellular SARS-CoV-2 Immunity Using ELISA and a Gold Nanoparticle-Based IGRA.International journal of molecular sciences · 2026Article
- CD8Cell reports. Medicine · 2026Review
- Computational identification of antigen-specific T cell groups through generative epitope modeling.iScience · 2026Article
- The challenge and promise of studying human antigen-specific T cells.Nature reviews. Immunology · 2026Review
- Induction of mucosal immune responses against SARS-CoV-2: a heterologous intramuscular mRNA-LNP prime/pulmonary recombinant subunit pull vaccination strategy.Scientific reports · 2026Article
- Arming Inactivated Enveloped Virus Vaccines with theVaccines · 2026Review
- Article
- Distinct CD8iScience · 2026Article
- A phase 1 clinical trial of a multi-antigen SARS-CoV DNA vaccine as a booster after dose three spike-based mRNA vaccinations.Molecular therapy. Advances · 2026Article
- Antigen-specific T-cell responses to SARS-CoV-2 vaccination after hematopoietic cell transplant or CAR T-cell therapy.Blood advances · 2026Article
- Comprehensive longitudinal profiling identifies differential frequency, epitope specificity, and effector function of CD8EBioMedicine · 2026Article
- Compartment-specific phase compensation between pulmonary T-Cell immunity and waning systemic responses in BA.5 breakthrough infection.Respiratory research · 2026Article
- Position-5-driven reorientation of an immunodominant HLA-A*24:02 SARS-CoV-2 epitope drives universal T cell escape.JCI insight · 2026Article
1,196 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
31 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS-CoV-2-specific memory T cells will likely prove critical for long-term immune protection against COVID-19. Here, we systematically mapped the functional and phenotypic landscape of SARS-CoV-2-specific T cell responses in unexposed individuals, exposed family members, and individuals with acute or convalescent COVID-19. Acute-phase SARS-CoV-2-specific T cells displayed a highly activated cytotoxic phenotype that correlated with various clinical markers of disease severity, whereas convalescent-phase SARS-CoV-2-specific T cells were polyfunctional and displayed a stem-like memory phenotype. Importantly, SARS-CoV-2-specific T cells were detectable in antibody-seronegative exposed family members and convalescent individuals with a history of asymptomatic and mild COVID-19. Our collective dataset shows that SARS-CoV-2 elicits broadly directed and functionally replete memory T cell responses, suggesting that natural exposure or infection may prevent recurrent episodes of severe COVID-19.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.